Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
0.2525
-0.0195 (-7.17%)
At close: Aug 28, 2026, 4:00 PM EDT
0.2575
+0.0050 (1.98%)
After-hours: Aug 28, 2026, 7:52 PM EDT

Mereo BioPharma Group Stock Forecast

MREO's stock price has decreased by -85.65% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 8 analysts polled by S&P Global, Mereo BioPharma Group stock has a consensus rating of "Buy" and an average price target of $2.01. The average 1-year stock price forecast is 696.04% higher than the current stock price, while the lowest is $1.01 (+300.00%) and the highest is $3.03 (+1,100.00%).

Price Target: $2.01 (+696.04%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$1.01$2.01$2.00$3.03
Change+300.00%+696.04%+692.08%+1100.0%

Analyst Ratings

The average analyst rating for Mereo BioPharma Group stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingFeb '26Mar '26Apr '26May '26Jul '26Aug '26
Strong Buy444444
Buy211111
Hold133332
Sell000001
Strong Sell000000
Total788888

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
J.P. Morgan
J.P. Morgan
Sell
Downgrades
n/a
SellDowngradesn/an/aAug 18, 2026
LifeSci Capital
LifeSci Capital
Hold
Maintains
n/a
HoldMaintainsn/an/aAug 15, 2026
Needham
Needham
Buy
Maintains
$3
BuyMaintains$3+1,088.12%Aug 11, 2026
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Maintains
$3
BuyMaintains$3+1,088.12%May 12, 2026
BTIG
BTIG
Buy
Maintains
$1
BuyMaintains$1+296.04%Mar 20, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
from 500.00K
Decreased by -100.00%
Revenue Next Year
19.20M
EPS This Year
n/a
EPS Next Year
n/a
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
49.37M-10.00M-500.00K-
Revenue Growth
------100.00%
Operating Income
-28.35M-52.70M-27.14M-45.72M-38.26M-33.17M
Net Income
17.23M-42.22M-29.47M-43.25M-41.88M-29.37M
Free Cash Flow
-9.08M-32.74M-14.17M-21.50M-17.92M18.71M
No. Analysts
-----5

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth202620272028
High
-100.0%
Avg
-100.0%
Low
-100.0%

EPS Forecast

EPS202620272028
High-
Avg-
Low-

EPS Growth

EPS Growth20272028
High-
Avg-
Low-